Purchase Order 75F40122P00012

<p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. for a MiSeq Silver Support Plan with a ceiling value of $388,924.75, effective through November 25, 2024, and dated June 18, 2019. Work is performed in Silver Spring, Maryland. The order is firm fixed price with no set-aside applied.</p>

The Food and Drug Administration awarded a $14,070 firm fixed-price purchase order to Illumina, Inc. for a service contract related to a MiSeq instrument on June 24, 2021, with completion targeted for June 29, 2023. The contract was issued without a small business set-aside designation, despite originating from a total small business solicitation posted on May 18, 2021. Performance of services will take place in Winchester, Massachusetts. Illumina, a San Diego-based biotechnology company...

<p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. for preventive maintenance service for two Illumina MiSeq instruments, with a ceiling value of $58,464.00 and an award date of April 13, 2022. Place of performance is Jefferson, Arkansas. The order carries no set-aside and firm fixed pricing. Ultimate completion date is July 19, 2027.</p>

<p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. for MiSeq service agreements covering serial numbers M04729 and M06865, valued at $159,155.75, with an award date of August 4, 2023. Performance occurs at Dauphin Island, Alabama. The order is firm fixed price with an ultimate completion date of August 3, 2028. No small business set-aside applies.</p>

The Food and Drug Administration awarded a purchase order to Illumina, Inc. for MiSeq Silver Support Plans covering preventative maintenance for five MiSeq instruments in the Center for Food and Applied Nutrition, with a ceiling value of $425,145.40 and an award date of August 31, 2024. The order is firm fixed price with no set-aside. Performance occurs in Laurel, Maryland through September 29, 2029, comprising a 12-month base period and four 12-month option periods. The procurement proceeded as...

<p>The Food and Drug Administration issued a purchase order to Illumina, Inc. for $66,483.01 on July 8, 2020, for preventive maintenance and repair of an Illumina MiSeq sequencing instrument. Work is performed at Jefferson, Arkansas. The order carries a firm fixed price and has an ultimate completion date of May 16, 2025. No set-aside was used.</p>

The Department of Health and Human Services Food and Drug Administration awarded a $474,577.44 firm fixed price purchase order for preventive maintenance and repair services for Illumina, Inc.'s MiSeq DNA sequencing systems. The contract was awarded on December 4, 2017 with a completion date of December 5, 2019. Illumina is a manufacturer of a range of genetic and genomic analysis instruments and reagents, and has provided similar products and services to support research and diagnostics at...

The Department of Health and Human Services Food and Drug Administration awarded a $67,963.80 firm fixed price purchase order to Illumina, Inc. for corrective, remedial, repair, and preventive maintenance services for Illumina's MiSeq sequencing systems. The contract has a period of performance through February 28, 2025 and was awarded on December 12, 2019. No set-aside designation was used for this award to support the FDA's medical device evaluation programs through ongoing maintenance and...

This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...

The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and related products, for the provision of a MiSeq sequencing instrument and a one-year preventative maintenance agreement. The total potential value of this contract is $109,857.00. Illumina has a history of providing sequencing systems and services to support genomic research and diagnostics across various federal...